Equities analysts expect that Burning Rock Biotech Limited (NASDAQ:BNR) will report earnings of ($0.11) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Burning Rock Biotech’s earnings, with estimates ranging from ($0.12) to ($0.10). The firm is expected to report its next quarterly earnings report on Tuesday, November 10th.
On average, analysts expect that Burning Rock Biotech will report full year earnings of ($0.52) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.38). For the next fiscal year, analysts forecast that the business will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.45) to ($0.32). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Burning Rock Biotech.
Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.18). The company had revenue of $15.14 million during the quarter.
BNR stock traded down $1.08 on Wednesday, reaching $20.75. 62,567 shares of the company’s stock were exchanged, compared to its average volume of 197,560. Burning Rock Biotech has a twelve month low of $18.64 and a twelve month high of $32.40.
About Burning Rock Biotech
Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests.
Recommended Story: Hedge Funds – How They Work For Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.